Bulletin of the School of Medicine (Baltimore, Md.)最新文献

The therapeutic effect and safety of the drugs for COVID-19: a systematic review and meta-analysis 新冠肺炎药物的疗效和安全性:系统评价和荟萃分析

Bulletin of the School of Medicine (Baltimore, Md.) Pub Date : 2020-10-07 DOI: 10.21203/rs.3.rs-89225/v1

R. Qiu, Jingwei Li, Yunhao Xiao, Ziyi Gao, Y. Weng, Qiran Zhang, Chengdi Wang, Han-lin Gong, Wei-min Li

{"title":"The therapeutic effect and safety of the drugs for COVID-19: a systematic review and meta-analysis","authors":"R. Qiu, Jingwei Li, Yunhao Xiao, Ziyi Gao, Y. Weng, Qiran Zhang, Chengdi Wang, Han-lin Gong, Wei-min Li","doi":"10.21203/rs.3.rs-89225/v1","DOIUrl":"https://doi.org/10.21203/rs.3.rs-89225/v1","url":null,"abstract":"\u0000 Background: Coronavirus disease 2019 (COVID-19) has spread almost all regions of the world and caused great loss to the whole body of mankind. Thus, numerous clinical trials were conducted to find specific medicine for COVID-19 recently. However, it remains unanswered whether they are beneficial. Objective: This study aimed to evaluate the efficiency and safety of the COVID-19 medicine. Methods: Studies were determined through searching PubMed, Embase, Cochrane Library and Medline. The clinical trials of COVID-19 medicine were involved with eligible end points containing mortality, discharge rate, rate of clinical improvement and rate of serious adverse events. The risk ratio (RR) was adopted for variables as effect magnitude with 95% confidence intervals (CI), and the random‐effects model was adopted for analysis. Results: A total of eleven RCTs and eleven Non-RCTs involving 12,796 patients were included in our study, whose intervening measures contained three major types of COVID-19 medicine, ACEI/ARB, antiviral medicine and chloroquine/hydroxychloroquine. Compared to control group, COVID-19 medicine has the obvious advantage in reducing discharge rate (RR, 1.18; 95% CI, 1.07-1.29, p<0. 05) and clinical improvement rate (RR, 1.15; 95% CI, 1.05-1.26, p<0. 05), no distinct effect on mortality (RR, 0.79; 95% CI, 0.53-1.17, p=0. 24). In addition, the serious adverse events rate (RR, 0.74; 95% CI, 0.62-0.88, p<0. 05) of COVID-19 medicine is lower than control group. Among different types of medicine, significant benefits in lowering the mortality seem to only occur in antiviral medicine. Conclusion: The results indicated antiviral medicine was potential drug of first choice recommended for COVID-19 treatment. Chloroquine/hydroxychloroquine therapy was not recommended for COVID-19 patients. Additionally, the ACEI/ARB could be adopted for COVID-19 treatment when combined with standard treatment.","PeriodicalId":86002,"journal":{"name":"Bulletin of the School of Medicine (Baltimore, Md.)","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83196393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Efficacy and safety of DPP-4 inhibitor in the treatment of patients with COVID-19 combined with diabetes mellitus a protocol for systematic review and meta-analysis DPP-4抑制剂治疗COVID-19合并糖尿病患者的疗效和安全性:系统评价和荟萃分析方案

Bulletin of the School of Medicine (Baltimore, Md.) Pub Date : 2020-09-03 DOI: 10.37766/inplasy2020.9.0015

Yan Liu, Hongyan Xie, Hongpan Gao, C. Xie

{"title":"Efficacy and safety of DPP-4 inhibitor in the treatment of patients with COVID-19 combined with diabetes mellitus a protocol for systematic review and meta-analysis","authors":"Yan Liu, Hongyan Xie, Hongpan Gao, C. Xie","doi":"10.37766/inplasy2020.9.0015","DOIUrl":"https://doi.org/10.37766/inplasy2020.9.0015","url":null,"abstract":"BACKGROUND: DM is a common chronic metabolic disease. COVID-19 is a large-scale infectious disease. Some studies have shown that DM is an independent risk factor that increases COVID-19 mortality or other adverse outcomes. There is currently no specific and effective drug treatment. More and more people realize that DPP-4 inhibitors may play a huge role in fighting COVID-19 combined with diabetes. However, there is no evidence-based medicine to confirm the effectiveness and safety of DPP-4 inhibitors in the treatment of COVID-19 patients with diabetes. Therefore, we will conduct a systematic review and meta-analysis to synthesize the existing clinical evidence. METHODS AND ANALYSIS: Electronic databases include CNKI, Wanfang, VIP, CBM database, Cochrane Library, PubMed, Web of Science, EMBASE, etc. We will retrieve each database from December 2019 to September 2020. At the same time, we will look for clinical trial registration and gray literature. This study only included clinical randomized controlled trials. The reviewers independently conduct literature selection, data analysis, quality analysis, and evaluation. The primary outcomes include mortality rate, morbidity, interleukin-6, tumor necrosis factor-alpha, clinical improvement, symptoms improvement, fasting blood glucose, 2-hour postprandial blood glucose, glycosylated hemoglobin, fasting insulin, adverse reactions, etc. Finally, we will conducted a meta-analysis through Review Manager Software version 5.3. RESULTS: The results will be published in peer-reviewed journals and presented at a relevant conference. CONCLUSION: This study will explore the effectiveness and safety of DPP-4 inhibitors in the treatment of COVID-19 patients with diabetes. It will provide evidence-based medical evidence for DPP-4 inhibitors in the treatment of diabetes with COVID-19. REGISTRATION NUMBER: INPLASY202090015.","PeriodicalId":86002,"journal":{"name":"Bulletin of the School of Medicine (Baltimore, Md.)","volume":"80 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86667537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

COVID-19 Infection Manifesting as a Severe Gastroparesis Flare: A Case Report COVID-19感染表现为严重胃轻瘫发作1例

Bulletin of the School of Medicine (Baltimore, Md.) Pub Date : 2020-06-15 DOI: 10.21203/rs.3.rs-28584/v1

Jun Song, R. Bhuta, Kamal Baig, H. Parkman, Z. Malik

{"title":"COVID-19 Infection Manifesting as a Severe Gastroparesis Flare: A Case Report","authors":"Jun Song, R. Bhuta, Kamal Baig, H. Parkman, Z. Malik","doi":"10.21203/rs.3.rs-28584/v1","DOIUrl":"https://doi.org/10.21203/rs.3.rs-28584/v1","url":null,"abstract":"\u0000 Background: Coronavirus Disease 2019 (COVID-19) is a disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which commonly presents with symptoms including fever, cough, and dyspnea. More recently, however, some patients have tested positive for COVID-19 after developing gastrointestinal (GI) symptoms either solely or in conjunction with respiratory symptoms. This may be due to SARS-CoV-2 infection of the GI tract. In patients with chronic GI illnesses, COVID-19 may initially present as a flare of their underlying GI conditions as viruses have historically been implicated in exacerbations of GI disorders, including gastroparesis. Case presentation: We report a case of a 37 year-old female with a history of diabetic gastroparesis who presented to the Emergency Department (ED) in a gastroparesis flare. Her symptoms in the ED failed to improve with fluids and anti-emetic medications. After developing a fever, she was tested and found to be positive for COVID-19.Conclusion: To our knowledge, at the present time, this is the first report of a patient with COVID-19 presenting with signs and symptoms of a gastroparesis flare. This case illustrates that patients with underlying GI disorders, such as gastroparesis, may have SARS-CoV-2 infections that present as an exacerbation of their underlying disorder. Initial presentation of these patients manifesting as a flare of their chronic GI disease, more severe than usual, should prompt an index of suspicion for COVID-19.","PeriodicalId":86002,"journal":{"name":"Bulletin of the School of Medicine (Baltimore, Md.)","volume":"54 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88155983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

PUBERTY AND GYNECOLOGY IN THE CUNA INDIANS. 库纳印第安人的青春期和妇科。

Bulletin of the School of Medicine (Baltimore, Md.) Pub Date : 1964-04-01

A W MCFADDEN

引用次数: 0

PSYCHOGALVANIC SKIN RESPONSE GUSTOMETRY. 心理电皮肤反应味觉测定。

Bulletin of the School of Medicine (Baltimore, Md.) Pub Date : 1964-04-01

S J BORSANYI, J QUINONES, C L BLANCHARD

引用次数: 0

THE REPRODUCTIVE BEHAVIOR OF THE ADOLESCENT FEMALE. 青春期雌性的生殖行为。

Bulletin of the School of Medicine (Baltimore, Md.) Pub Date : 1964-01-01

A L HASKINS